Incidence of COVID-19 Vaccination-Related Uveitis and Effects of Booster Dose in a Tertiary Uveitis Referral Center
BackgroundWe report vaccine and booster-related uveitis in Singapore, a country with high vaccination and booster rates to highlight the differences and potential role of prophylactic treatment for sight-threatening infectious uveitis.MethodsClinical data extracted from the de-identified uveitis dat...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.925683/full |
| _version_ | 1818214511310536704 |
|---|---|
| author | Milton C. Chew Shaan Wiryasaputra Meihui Wu Wei Boon Khor Anita S. Y. Chan Anita S. Y. Chan Anita S. Y. Chan |
| author_facet | Milton C. Chew Shaan Wiryasaputra Meihui Wu Wei Boon Khor Anita S. Y. Chan Anita S. Y. Chan Anita S. Y. Chan |
| author_sort | Milton C. Chew |
| collection | DOAJ |
| description | BackgroundWe report vaccine and booster-related uveitis in Singapore, a country with high vaccination and booster rates to highlight the differences and potential role of prophylactic treatment for sight-threatening infectious uveitis.MethodsClinical data extracted from the de-identified uveitis database in Singapore National Eye Center. Six patients (eight eyes) developed uveitis within 14 days after undergoing COVID-19 vaccination (primary and/or booster).ResultsAll patients received two doses of COVID-19 vaccination, and 1.39% (6/431) developed COVID-19 vaccine-related uveitis. Fifty-percent% (3/6) with non-infectious anterior uveitis (NIAU) presented with a non-granulomatous anterior uveitis (AU). The remaining (3/6) presenting with a granulomatous AU were diagnosed with reactivation of cytomegalovirus, varicella-zoster virus and toxoplasma chorioretinitis, respectively. All the patients responded to definitive treatment specific to their diagnosis. The mean visual acuity at presentation was 0.36 ± 0.20 logMAR and improved to 0.75 ± 0.09 (p = 0.009). Mean time from vaccination to uveitis was 9.7 (range: 3–14) days. All patients developed uveitis after second vaccination dose. 16.67% (1/6) patients had a recurrence after the third booster dose. None of the three patients with infectious uveitis developed recurrence but had received maintenance therapy up to or during the booster.ConclusionUveitis after COVID-19 vaccination is uncommon. In our series, a higher rate of reactivations of latent infections was seen. With definitive treatment, all cases were self-limited without systemic sequelae. Prophylactic treatment during booster vaccine may prevent reactivation of sight-threatening infections and reduce morbidity although risk-benefits should be considered for individual patients given the low rate of occurrence. |
| first_indexed | 2024-12-12T06:21:21Z |
| format | Article |
| id | doaj.art-e0dc7d0c36fc44f28aefb33b672c8da3 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-12T06:21:21Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-e0dc7d0c36fc44f28aefb33b672c8da32022-12-22T00:34:53ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-06-01910.3389/fmed.2022.925683925683Incidence of COVID-19 Vaccination-Related Uveitis and Effects of Booster Dose in a Tertiary Uveitis Referral CenterMilton C. Chew0Shaan Wiryasaputra1Meihui Wu2Wei Boon Khor3Anita S. Y. Chan4Anita S. Y. Chan5Anita S. Y. Chan6Singapore National Eye Centre, Singapore, SingaporeSingapore National Eye Centre, Singapore, SingaporeTranslational Ophthalmic Pathology Platform, Singapore Eye Research Institute, Singapore, SingaporeSingapore National Eye Centre, Singapore, SingaporeSingapore National Eye Centre, Singapore, SingaporeTranslational Ophthalmic Pathology Platform, Singapore Eye Research Institute, Singapore, SingaporeOphthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Graduate Medical School, Singapore, SingaporeBackgroundWe report vaccine and booster-related uveitis in Singapore, a country with high vaccination and booster rates to highlight the differences and potential role of prophylactic treatment for sight-threatening infectious uveitis.MethodsClinical data extracted from the de-identified uveitis database in Singapore National Eye Center. Six patients (eight eyes) developed uveitis within 14 days after undergoing COVID-19 vaccination (primary and/or booster).ResultsAll patients received two doses of COVID-19 vaccination, and 1.39% (6/431) developed COVID-19 vaccine-related uveitis. Fifty-percent% (3/6) with non-infectious anterior uveitis (NIAU) presented with a non-granulomatous anterior uveitis (AU). The remaining (3/6) presenting with a granulomatous AU were diagnosed with reactivation of cytomegalovirus, varicella-zoster virus and toxoplasma chorioretinitis, respectively. All the patients responded to definitive treatment specific to their diagnosis. The mean visual acuity at presentation was 0.36 ± 0.20 logMAR and improved to 0.75 ± 0.09 (p = 0.009). Mean time from vaccination to uveitis was 9.7 (range: 3–14) days. All patients developed uveitis after second vaccination dose. 16.67% (1/6) patients had a recurrence after the third booster dose. None of the three patients with infectious uveitis developed recurrence but had received maintenance therapy up to or during the booster.ConclusionUveitis after COVID-19 vaccination is uncommon. In our series, a higher rate of reactivations of latent infections was seen. With definitive treatment, all cases were self-limited without systemic sequelae. Prophylactic treatment during booster vaccine may prevent reactivation of sight-threatening infections and reduce morbidity although risk-benefits should be considered for individual patients given the low rate of occurrence.https://www.frontiersin.org/articles/10.3389/fmed.2022.925683/fullCOVID-19vaccinationuveitisboostercoronavirus-19 disease |
| spellingShingle | Milton C. Chew Shaan Wiryasaputra Meihui Wu Wei Boon Khor Anita S. Y. Chan Anita S. Y. Chan Anita S. Y. Chan Incidence of COVID-19 Vaccination-Related Uveitis and Effects of Booster Dose in a Tertiary Uveitis Referral Center Frontiers in Medicine COVID-19 vaccination uveitis booster coronavirus-19 disease |
| title | Incidence of COVID-19 Vaccination-Related Uveitis and Effects of Booster Dose in a Tertiary Uveitis Referral Center |
| title_full | Incidence of COVID-19 Vaccination-Related Uveitis and Effects of Booster Dose in a Tertiary Uveitis Referral Center |
| title_fullStr | Incidence of COVID-19 Vaccination-Related Uveitis and Effects of Booster Dose in a Tertiary Uveitis Referral Center |
| title_full_unstemmed | Incidence of COVID-19 Vaccination-Related Uveitis and Effects of Booster Dose in a Tertiary Uveitis Referral Center |
| title_short | Incidence of COVID-19 Vaccination-Related Uveitis and Effects of Booster Dose in a Tertiary Uveitis Referral Center |
| title_sort | incidence of covid 19 vaccination related uveitis and effects of booster dose in a tertiary uveitis referral center |
| topic | COVID-19 vaccination uveitis booster coronavirus-19 disease |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.925683/full |
| work_keys_str_mv | AT miltoncchew incidenceofcovid19vaccinationrelateduveitisandeffectsofboosterdoseinatertiaryuveitisreferralcenter AT shaanwiryasaputra incidenceofcovid19vaccinationrelateduveitisandeffectsofboosterdoseinatertiaryuveitisreferralcenter AT meihuiwu incidenceofcovid19vaccinationrelateduveitisandeffectsofboosterdoseinatertiaryuveitisreferralcenter AT weiboonkhor incidenceofcovid19vaccinationrelateduveitisandeffectsofboosterdoseinatertiaryuveitisreferralcenter AT anitasychan incidenceofcovid19vaccinationrelateduveitisandeffectsofboosterdoseinatertiaryuveitisreferralcenter AT anitasychan incidenceofcovid19vaccinationrelateduveitisandeffectsofboosterdoseinatertiaryuveitisreferralcenter AT anitasychan incidenceofcovid19vaccinationrelateduveitisandeffectsofboosterdoseinatertiaryuveitisreferralcenter |